Related Experiment Video
Updated: Jan 13, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
Updates in the Management of Immune-Mediated Necrotizing Myopathy
Suur Biliciler1, Eleni Tiniakou2
1Department of Neurology, The University of Texas Health Science Center at Houston, McGovern Medical School, 6431 Fannin Street, MSE R466, Houston, TX 77030, USA.
None:
While the treatment landscape of immune-mediated necrotizing myopathy continues to advance, current approaches still rely heavily on expert consensus, given a lack of robust clinical trial data. A deeper understanding of immunopathogenesis remains essential for more effective treatments. Glucocorticoids remain first-line, but steroid-sparing agents have improved long-term outcomes. IVIG and rituximab are effective in refractory cases, and emerging therapies like CAR-T cells show promise. Exercise is increasingly recognized for its impact. The future lies in precision medicine, customizing therapies based on antibody profiles and biomarkers, along with exploring innovative strategies, such as supplements, to improve outcomes and quality of life.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Cardiomyopathy V: Interprofessional Care
Nephrotic Syndrome III : Nursing Management

